View this interactive prIME Infographic to learn more about PARP inhibition in ovarian cancer, including mechanism of action, biomarkers, recent clinical trial results, and future directions.
Sep 28, 2017
Sep 28, 2018
Amit Oza, MD, FRCPC, MBBSPrincess Margaret Hospital
University of Toronto
Toronto, Ontario, Canada
Eric Pujade-Lauraine, MD, PhDCentre Hospitalier Universitaire Hôtel-Dieu
- Ovarian cancer overview
- Rationale and mechanism of action of PARP inhibitors
- Clinical trial data for PARP inhibitors in ovarian cancer
- Biomarkers and patient selection
- Ongoing trials and future directions
This educational activity is specifically designed for gynecologic oncologists, medical oncologists, and other healthcare providers involved in the management of patients with advanced ovarian cancer.
After successful completion of this educational activity, participants should be able to:
- Describe the mechanism of action of PARP inhibitors and identify predictive biomarkers of sensitivity to these agents
- Assess emerging clinical data and ongoing trials involving PARP inhibitors for patients with BRCA 1/2-mutant and BRCA 1/2-wildtype ovarian cancer
This educational activity is supported by a grant from AstraZeneca.
Independent Medical Education (IME)
This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.
This activity is provided by prIME Oncology.
Disclosure of Relevant Financial Relationships
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
Dr Gralla has disclosed that he has received compensation for speaking and teaching engagements from Chugai, Galenica, Helsinn SA, and Merck. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Kaasa has disclosed that he has ownership interest in Eir Solutions. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Molassiotis has disclosed that he has received consulting fees from Helsinn SA, Merck & Co Ltd, and Tesaro. He has performed contracted research/received support from Acacia Pharma. Dr Molassiotis has also received fees for non-CME services directly from commercial interest or their agents from Helsinn SA and Merck & Co Ltd. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Strasser has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
The employees of prIME Oncology have disclosed:
- Ronald Viggiani, MD (medical director content reviewer/planner) – no relevant financial relationships
- Briana Betz, PhD (Scientific content reviewer/planner) – no relevant financial relationships
- Trudy Stoddert, ELS (editorial content reviewer) – no relevant financial relationships
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.